USP22 and cancer: In hepatocellular carcinoma, USP22 knockdown or inhibition via agents like SO2 markedly increases the sensitivity of HCC LR and primary HCC cells to lenvatinib, while also diminishing Treg-mediated immunosuppression and enhancing CD8+ T cell infiltration, suggesting a promising role in cancer immunotherapy (270, 271).